These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35482472)

  • 1. Threshold of Quantitative Cytomegalovirus DNA PCR for Preemptive Treatment in Pediatric Hematopoietic Stem Cell Transplant Recipients.
    Ahn B; Yun KW; Hong KT; Choi JY; Kang HJ; Seong MW; Kim TS; Ahn SJ; Choi EH
    J Pediatr Hematol Oncol; 2023 Mar; 45(2):e200-e207. PubMed ID: 35482472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients.
    Cardeñoso L; Pinsky BA; Lautenschlager I; Aslam S; Cobb B; Vilchez RA; Hirsch HH
    J Clin Virol; 2013 Feb; 56(2):108-12. PubMed ID: 23146665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients.
    Choi SM; Lee DG; Lim J; Park SH; Choi JH; Yoo JH; Lee JW; Kim Y; Han K; Min WS; Shin WS; Kim CC
    J Korean Med Sci; 2009 Aug; 24(4):571-8. PubMed ID: 19654935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.
    Gimeno C; Solano C; Latorre JC; Hernández-Boluda JC; Clari MA; Remigia MJ; Furió S; Calabuig M; Tormo N; Navarro D
    J Clin Microbiol; 2008 Oct; 46(10):3311-8. PubMed ID: 18753357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L; Wang Y; Yan CH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
    Tan SK; Waggoner JJ; Pinsky BA
    J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Ishii K; Onishi Y; Miyamura N; Fukuhara N; Ishizawa K; Nakanishi M; Ohnaka S; Miyasaka T; Kanno E; Kawakami K; Harigae H; Kaku M
    J Med Virol; 2017 Jul; 89(7):1265-1273. PubMed ID: 28165158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
    Nichols WG; Corey L; Gooley T; Drew WL; Miner R; Huang M; Davis C; Boeckh M
    Blood; 2001 Feb; 97(4):867-74. PubMed ID: 11159510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the CMV antigenemia test and CMV-DNA PCR results in solid organ transplant recipients].
    Özkarata E; Özbek ÖA; Avkan Oğuz V; Sayıner AA
    Mikrobiyol Bul; 2016 Jan; 50(1):44-52. PubMed ID: 27058328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison between CMV quantitative PCR and CMV-pp65 antigen test for detection of CMV infection in allogeneic hematopoietic stem cell transplantation].
    Zhai WJ; Wei JL; Zhao MF; Wang M; Zhou Z; Liu P; Mu H; Feng SZ; Han MZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1522-6. PubMed ID: 20030939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytomegalovirus detection by real-time PCR and pp65-antigen test in hematopoietic stem cell transplant recipients: a challenge in low and middle-income countries.
    Breda G; Almeida B; Carstensen S; Bonfim CM; Nogueira MB; Vidal LR; Almeida SM; Raboni SM
    Pathog Glob Health; 2013 Sep; 107(6):312-9. PubMed ID: 24188241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients.
    Cortez KJ; Fischer SH; Fahle GA; Calhoun LB; Childs RW; Barrett AJ; Bennett JE
    J Infect Dis; 2003 Oct; 188(7):967-72. PubMed ID: 14513415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients.
    Sanghavi SK; Abu-Elmagd K; Keightley MC; St George K; Lewandowski K; Boes SS; Bullotta A; Dare R; Lassak M; Husain S; Kwak EJ; Paterson DL; Rinaldo CR
    J Clin Virol; 2008 Aug; 42(4):335-42. PubMed ID: 18495527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.
    Green ML; Leisenring W; Stachel D; Pergam SA; Sandmaier BM; Wald A; Corey L; Boeckh M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1687-99. PubMed ID: 22683614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.
    Boeckh M; Huang M; Ferrenberg J; Stevens-Ayers T; Stensland L; Nichols WG; Corey L
    J Clin Microbiol; 2004 Mar; 42(3):1142-8. PubMed ID: 15004066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection.
    Kalpoe JS; Kroes AC; de Jong MD; Schinkel J; de Brouwer CS; Beersma MF; Claas EC
    J Clin Microbiol; 2004 Apr; 42(4):1498-504. PubMed ID: 15070995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.